For citations:
Akimova A.A., Banshchikova N.E., Sizikov A.E., Mullagaliev A.A., Letyagina E.A., Ilina N.A., Kurochkina Yu.D., Ubshaeva Yu.B., Omelchenko V.O., Chumasova O.A., Shkaruba N.S., Korolev M.A. Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic. Rheumatology Science and Practice. 2023;61(1):25–33. (In Russ.) https://doi.org/10.47360/1995-4484-2023-25-33